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Abstract
Background:  The 2005 International Diabetes Federation (IDF) definition of the metabolic
syndrome was designed to be useful worldwide, but to date few prevalence studies have used that
definition in European populations. We estimated the age- and sex-stratified prevalence of IDF-
defined metabolic syndrome in a county of Norway and compared it with the prevalence estimated
using the revised National Cholesterol Education Program-Adult Treatment Panel-III definition
(2005 ATP III).
Methods: Cross-sectional analysis of 10,206 participants aged 20–89 years in the Nord-Trøndelag
Health Study 1995–97 (HUNT 2).
Results:  Prevalence of IDF-defined metabolic syndrome was 29.6% (95% CI: 28.8 to 30.5),
compared to 25.9% (95% CI: 25.0 to 26.7) using the 2005 ATP III criteria. The prevalence of IDF-
defined metabolic syndrome increased from 11.0% in the 20–29 years age group to 47.2% in the
80–89 years group in men, and from 9.2% to 64.4% for women in the corresponding age groups.
Among men and women aged ≥60 years, the IDF criteria classified 56.7% and 75.0%, respectively,
as having central obesity, and 89.3% and 90.9%, respectively, as being hypertensive.
Conclusion: According to both definitions, the prevalence of the metabolic syndrome increased
strongly with age. The IDF and the American Heart Association/National Heart, Lung, and Blood
Institute guidelines for clinical management of metabolic syndrome would classify a high proportion
of elderly Norwegians as in need of overall risk assessment for cardiovascular disease.
Background
The metabolic syndrome has been identified as a cluster
of risk factors for atherosclerotic cardiovascular disease
and type 2 diabetes, and its occurrence has been described
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as a global epidemic [1]. In the past few years, increased
attention to the syndrome has led to several attempts to
develop a definition accepted worldwide. In 1998, the
World Health Organization (WHO) proposed a set of
diagnostic criteria [2], followed by definitions from the
European Group for the Study of Insulin Resistance
(EGIR) in 1999 [3], and by the National Cholesterol Edu-
cation Program's Adult Treatment Panel III (ATP III) in
2001 [4]. These definitions agreed that hyperglycemia,
obesity, dyslipidaemia, and hypertension are core compo-
nents of the metabolic syndrome, but they differed in the
details and criteria. The 2001 ATP III definition has been
regarded as probably the most practical for alerting clini-
cians to subjects at risk [5]. However, the cut-off values for
obesity have been criticized for limited applicability in
various ethnic groups [6]. In 2005, a modification (2005
ATP III) by the American Heart Association and National
Heart, Lung, and Blood Institute (AHA/NHLBI) was pub-
lished. The 2001 ATP III criteria were maintained except
for a reduced threshold for hyperglycemia and some
minor modifications [7].
In 2005, the International Diabetes Federation (IDF)
issued new criteria that further modified the ATP III defi-
nition [6,8]. The IDF considered that visceral obesity is
highly correlated with insulin resistance (which was a core
factor in the WHO definition, but cumbersome to assess
in clinical practice), and thus essential for diagnosis of the
metabolic syndrome. The waist circumference thresholds
were lower than the ATP III recommendations and were
made ethnicity-specific in an effort to make the definition
useful in any population. The IDF definition required cen-
tral obesity plus any two of four components: elevated
triglycerides, low high-density lipoprotein (HDL) choles-
terol, hypertension and elevated plasma glucose.
The IDF recommended, "Management of the condition
should be aggressive and uncompromising in its aim to
reduce the risk of cardiovascular disease and type 2 diabe-
tes. Patients should undergo a full cardiovascular risk
assessment" [8]. Similarly, the 2005 AHA/NHLBI scien-
tific statement recommended, "to reduce lifetime risk for
atherosclerotic cardiovascular disease, all individuals
found to have the metabolic syndrome deserve long-term
management and follow-up in the clinical setting" [7].
Thus, information about the prevalence of metabolic syn-
drome is essential in order to estimate the health care
resources needed for making the diagnosis, counselling
about lifestyle changes, and doing overall risk assessment
for cardiovascular disease. To date, the prevalence of met-
abolic syndrome defined by the IDF or the 2005 ATP III
criteria is unknown in the general population in the
northern part of Europe.
In this study, we estimated age- and sex-specific preva-
lence rates of the metabolic syndrome in the Norwegian
population participating in the Nord-Trøndelag Health
Study 1995–97 using the IDF definition, compared the
rates with those obtained using the 2005 ATP III defini-
tion, and estimated the concordance between the two def-
initions.
Methods
Sample characteristics
Our cross-sectional data were derived from the Nord-
Trøndelag Health Study (HUNT 2) 1995–97, a Norwegian
population study which is described in detail elsewhere
[9]. Briefly, all inhabitants aged 20 years and above in the
county were invited to a general health study. Data were
obtained from physical tests, blood samples, and from
questionnaires that covered demographic characteristics,
somatic illnesses, somatic and mental symptoms, medica-
tions, life style, and health-related behaviour. Among a
total of 92,205 individuals aged 20 to 89 years, 65,753
(71.3%) participated, and 63,600 individuals had valid
data for this study. As the HUNT study is a large survey
where participants were examined at different time points
during the day, it was impractical to keep everyone fasting.
Blood sampling was done whenever the participants
attended, but time since the last meal was noted. In all,
10,206 individuals (16% of the 63,600) reported ≥4
hours since their last meal, and they were included in the
present study. Based on data from the fourth (2394) of the
included sample that reported ≥9 hours fasting, triglycer-
ides and glucose levels for individuals fasting 4–8 hours
were adjusted before further analyses were performed.
In the HUNT 2 study, blood pressure was measured by
specially trained nurses, using a Dinamap 845XT (Criti-
con, Tampa, Florida, USA) based on oscillometry. Cuff
size was adjusted according to the arm circumference. The
Dinamap was started after the subject had been seated for
two minutes with the cuff on the arm, and the arm resting
on a table. Blood pressure was measured three times at
one-minute intervals. The mean of the second and third
reading was used in this study.
Blood samples were analysed at Levanger Hospital on a
Hitachi 911 autoanalyser. Glucose was measured with an
enzymatic hexokinase method, total cholesterol and HDL
cholesterol applying an enzymatic colorimetric cholester-
olesterase method and triglycerides by an enzymatic
colorimetric method. Participants with a history of diabe-
tes were invited to an additional fasting blood test for glu-
cose, C-peptide and glutamic acid decarboxylase
antibodies. Based on these and information on start of
insulin treatment, diabetes types 1 and 2 were identified.BMC Public Health 2007, 7:220 http://www.biomedcentral.com/1471-2458/7/220
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Definitions of the metabolic syndrome
The IDF definition [8] requires central obesity (measured
as ethnic-specific waist circumference; for population of
European origin: ≥94 cm in men and ≥80 cm in women)
plus any two of four components: 1) serum triglycerides
≥1.7 mmol/L or specific treatment for this lipid abnormal-
ity; 2) HDL cholesterol <1.03 mmol/L in men and <1.29
mmol/L in women or specific treatment for this lipid
abnormality; 3) blood pressure ≥130/≥85 or treatment for
previously diagnosed hypertension; and 4) fasting plasma
glucose ≥5.6 mmol/L or previously diagnosed type 2 dia-
betes. Data on specific treatment for lipid abnormalities
were not available in the HUNT 2 study; however, such
treatment was infrequent in Norway at that time.
The 2005 ATP III definition [7] requires the presence of
three or more of five components: 1) waist circumference
>102 cm in men and >88 cm in women, 2) triglycerides
≥1.7 mmol/L or drug treatment for elevated triglycerides,
2) HDL cholesterol <1.03 mmol/L in men and <1.29
mmol/L in women or drug treatment for reduced HDL
cholesterol, 4) blood pressure ≥130/≥85 mm Hg or drug
treatment for previously diagnosed hypertension, and 5)
fasting plasma glucose ≥5.6 mmol/L or drug treatment for
elevated glucose.
Statistical analysis
Descriptive statistics were used to estimate age and the
components of the metabolic syndrome in the 10,206
participants fasting ≥4 hours (the included sample) in
relation to sex and the IDF defined metabolic syndrome.
Distribution (means with 95% confidence interval, CI) of
plasma glucose, triglycerides, and HDL cholesterol in rela-
tion to time since the last meal were explored with graphs
and regression analyses.
After more than four hours fasting, we found no statistical
significant association between time since the last meal
and HDL cholesterol. However, triglycerides were weakly
and negatively associated with time since the last meal
(0.042 mmol/L decrease per hour fasting from 4 to 9),
whereas glucose was weakly and positively associated
(0.061 mmol/L increase per hour fasting from 4 to 9). We
adjusted the triglyceride and glucose levels for time since
the last meal based on regression coefficients obtained
from linear regression models with triglycerides and glu-
cose, respectively, as the dependent variable, and time
since the last meal (range 4–9 hours) as independent var-
iable (encoded categorically), all models adjusted for age
(continuous measure) and sex. We regarded individuals
reporting ≥9 hours since the last meal as fasting and used
their triglyceride and glucose levels as references for the
adjustments. Triglyceride levels were subtracted 0.208,
0.135, 0.044, 0.076, and 0.014 mmol/L for individuals
reporting fasting for 4, 5, 6, 7, and 8 hours, respectively.
Correspondingly, glucose levels were added 0.307, 0.284,
0.216, 0.272, and 0.006 mmol/L.
We calculated prevalence estimates of IDF-defined meta-
bolic syndrome for the included sample, for men and
women, and for sex-stratified 10-years age groups. Sex-
stratified prevalence rates of the other components of IDF-
defined metabolic syndrome in relation to central obesity
were estimated. Prevalence of the metabolic syndrome
estimated by the IDF and the 2005 ATP III definitions was
presented as age- and sex-stratified graphs, and concord-
ance between the two definitions was estimated by classi-
fication in percentages, and by κ statistic.
Finally, for the purpose of examining the representative-
ness of the included sample, we estimated sex-stratified
means and proportions (with 95% CI) of age and the
components of metabolic syndrome in the 10,206 partic-
ipants fasting ≥4 hours versus the 53,394 participants fast-
ing <4 hours. We compared prevalence of metabolic
syndrome in the two samples by excluding glucose and
triglycerides from the IDF and 2005 ATP III definitions,
with that minimizing the effects of fasting. Accordingly,
the IDF-proxy for metabolic syndrome was defined as cen-
tral obesity plus any two of three components (low HDL
cholesterol, hypertension, or type 2 diabetes), and the
ATP-proxy as any three of four components (central obes-
ity, low HDL cholesterol, hypertension, or type 2 diabe-
tes). The prevalence of the two proxies was calculated.
Logistic regression analyses were employed (with fasting
≥4 hours as a dichotomous independent variable) for cat-
egorical variables and a t test for z-scores of continuous
variables (See Results, last paragraph).
Two-sided P < 0.05 indicated statistical significance. All
analyses were done with SPSS software (version 14.0;
SPSS Inc, USA).
Ethics
All participants in the HUNT study gave written informed
consent. The Norwegian Data Inspectorate and the
Regional Committee for Medical Research Ethics
approved the study.
Results
Characteristics of the included men and women with and
without IDF-defined metabolic syndrome are shown in
Table 1.
IDF-defined metabolic syndrome
The prevalence of IDF-defined metabolic syndrome was
29.6% (95% CI: 28.8 to 30.5). This was similar in men
(29.0%, 95% CI: 27.7 to 30.2) and in women (30.3%,
95% CI: 29.0 to 31.6). The prevalence increased with ageBMC Public Health 2007, 7:220 http://www.biomedcentral.com/1471-2458/7/220
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right up to the ninth decade, especially among women
(Table 2).
The prevalence of IDF-defined central obesity was 42.0%
among men and 53.4% among women. Among men and
women aged 60 years or more, the IDF criteria classified
56.7% and 75.0%, respectively, as having central obesity,
and 89.3% and 90.9%, respectively, as hypertensive.
In men with central obesity, 83.3% had high blood pres-
sure or used antihypertensive medications, 46.9% had
high triglycerides, 40.2% had high glucose or type 2 dia-
betes, and 38.0% had low HDL cholesterol, by the IDF cri-
teria. In women, the corresponding percentages were
72.3%, 34.1%, 37.2% and 36.1%. In total, 69.0% of the
men and 56.7% of the women with central obesity had at
least two additional components defining the metabolic
syndrome. Central obesity without any additional com-
ponent was infrequent (5.9% in men and 12.6% in
women).
IDF versus 2005 ATP III
The IDF definition of the metabolic syndrome gave a
higher prevalence in all demographic groups except in
men aged 20–29 years, compared to estimates by the
2005 ATP III criteria (Figure 1). In the entire study sample,
the prevalence of the syndrome was 25.9% (95% CI: 25.0
to 26.7) by the 2005 ATP III criteria; the prevalence was
26.8% in men and 25.0% in women.
By applying either the IDF or the 2005 ATP III criteria,
34.5% of the participants were defined as having the met-
Age-specific prevalence of metabolic syndrome according to  the definition by the International Diabetes Federation (IDF),  compared to the revised definition by the National Choles- terol Education Program-Adult Treatment Panel III (2005  ATP III), among men and women in the HUNT 2 population Figure 1
Age-specific prevalence of metabolic syndrome according to 
the definition by the International Diabetes Federation (IDF), 
compared to the revised definition by the National Choles-
terol Education Program-Adult Treatment Panel III (2005 
ATP III), among men and women in the HUNT 2 population.
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Table 1: Characteristics of participants1 in relation to IDF-defined metabolic syndrome, the HUNT 2 study
Men Women
No metabolic syndrome Metabolic syndrome No metabolic syndrome Metabolic syndrome
N (%) 3622 (71.1) 1479 (29.0) 3558 (69.7) 1547 (30.3)
Age, y 45.8 ± 16.6 55.0 ± 16.3 44.8 ± 16.1 60.2 ± 16.2
Systolic BP, mm Hg 136.9 ± 18.7 148.8 ± 19.9 130.1 ± 21.1 153.6 ± 24.3
Diastolic BP, mm Hg 81.2 ± 11.7 88.8 ± 11.7 77.1 ± 11.2 86.7 ± 12.9
Waist circumference, cm 88.2 ± 7.9 101.9 ± 7.3 77.4 ± 9.7 92.9 ± 9.9
HDL cholesterol, mmol/L 1.32 ± 0.33 1.10 ± 0.31 1.59 ± 0.37 1.30 ± 0.36
Triglycerides, mmol/L 1.31 ± 0.91 2.30 ± 1.40 0.99 ± 0.55 2.02 ± 1.15
Glucose, mmol/L 5.35 ± 0.93 5.93 ± 1.67 5.18 ± 0.60 5.98 ± 1.52
Type 2 diabetes, % 0.8 3.6 0.2 6.0
Antihypertensive 
medication, %
6.6 19.4 5.6 30.2
Waist/hip ratio 0.88 ± 0.05 0.95 ± 0.05 0.78 ± 0.05 0.85 ± 0.06
BMI, kg/m2 25.4 ± 3.0 29.8 ± 3.3 25.0 ± 4.1 30.2 ± 4.5
Total cholesterol, mmol/L 5.74 ± 1.17 6.25 ± 1.14 5.75 ± 1.29 6.69 ± 1.37
Data are numbers, means ± standard deviation, or percentages.
HUNT, the Nord-Trøndelag Health study; IDF, the International Diabetes Federation; BP, blood pressure; HDL, high-density lipoprotein; BMI, body 
mass index.
1Fasting ≥4 hours.BMC Public Health 2007, 7:220 http://www.biomedcentral.com/1471-2458/7/220
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abolic syndrome (21.0% by both criteria, 8.6% by IDF
only, and 4.9% by 2005 ATP III only), and 65.5% as not
having the metabolic syndrome, providing a concordant
classification for 86.5% of the participants. Overall, agree-
ment between the IDF and the 2005 ATP III criteria was
good (total κ 0.66, men κ 0.57, women κ 0.76). Although
κ showed some variations between sex-specific 10-year
age groups, there were no age trends.
According to the higher threshold for central obesity in
the 2005 ATP III criteria, the prevalence of obesity was
only one third (13.5%) in men and one half (27.2%) in
women as compared to the prevalence obtained by the
IDF criteria.
Representativeness of the included sample
There were minor differences between the fasting (the
included sample) and the non-fasting participants in the
HUNT 2 study (Table 3). Fasting participants were on the
average one year younger than non-fasting participants.
For some of the components of metabolic syndrome, we
found statistically significant differences in one or both
sexes. Although statistically significant, these differences
were minor, except for the glucose and triglyceride levels
that differed somewhat more, as expected.
We found no statistically significant difference between
the fasting and the non-fasting samples in the prevalence
of the IDF- or ATP-proxies of metabolic syndrome, neither
in sex-stratified analyses (Table 3) nor in analyses strati-
fied by sex and 10-year age groups (data not shown).
Table 2: Prevalence of IDF-defined metabolic syndrome and its components in sex and age groups
IDF-defined 
metabolic syndrome
Obligate criterion Additional criteria
Central obesity1 Hyper-
triglyceridaemia2
Low HDL chol-
esterol3
High blood 
pressure4 or 
medication use
High plasma 
glucose5 or type 2 
diabetes
N %  ( 9 5 %  C I ) % %%%%
Men
20–29 yr 808 11.0 
(8.9 – 13.2)
20.8 19.8 28.5 59.8 13.6
30–39 yr 966 20.9 
(18.3 – 23.5)
34.1 29.9 27.4 58.5 22.8
40–49 yr 1065 27.6 
(24.9 – 30.3)
40.9 38.7 30.9 69.4 28.8
50–59 yr 848 32.7 
(29.5 – 35.8)
48.2 35.1 24.5 77.9 37.4
60–69 yr 665 41.7 
(37.9 – 45.4)
55.2 37.0 26.9 87.1 46.9
70–79 yr 569 44.8 
(40.7 – 48.9)
56.8 36.6 31.1 90.7 52.9
80–89 yr 180 47.2 
(39.9 – 54.5)
62.2 40.0 31.1 93.3 57.2
20–89 yr 5101 29.0 
(27.7 – 30.2)
42.0 33.3 28.3 72.8 32.7
Women
20–29 yr 807 9.2 
(7.2 – 11.2)
30.5 7.6 28.4 21.8 8.6
30–39 yr 877 14.1 
(11.8 – 16.4)
39.0 10.6 27.5 29.4 14.1
40–49 yr 1014 21.8 
(19.3 – 24.3)
48.7 17.3 25.7 47.7 21.1
50–59 yr 862 30.0 
(27.0 – 33.1)
56.5 22.5 21.3 70.5 30.2
60–69 yr 645 49.0 
(45.1 – 52.9)
70.7 34.7 26.7 86.7 45.6
70–79 yr 661 60.4 
(56.6 – 64.1)
77.8 40.5 31.3 94.1 52.6
80–89 yr 239 64.4 
(58.4 – 70.5)
78.7 44.4 38.1 93.7 58.6
20–89 yr 5105 30.3 
(29.0 – 31.6)
53.4 22.0 27.1 57.4 28.4
IDF, the International Diabetes Federation; HDL, high-density lipoprotein; CI, confidence interval.
1Waist circumference ≥94 cm in men, ≥80 cm in women.
2Triglycerides ≥1.7 mmol/L.
3HDL cholesterol <1.03 mmol/L in men, <1.29 mmol/L in women.
4Systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg.
5Plasma glucose ≥5.6 mmol/L.BMC Public Health 2007, 7:220 http://www.biomedcentral.com/1471-2458/7/220
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Discussion
Applying the IDF definition in a large Norwegian popula-
tion aged 20–89 years classified 29.6% as having the met-
abolic syndrome. The prevalence was highly age-
dependent. This was evident especially in women, with a
sevenfold increase in prevalence from age group 20–29
years to age group 80–89 years.
The IDF emphasizes central obesity as an essential crite-
rion for the metabolic syndrome, due to the evidence link-
ing ethnicity-specific waist circumference to
cardiovascular disease and to the other components of the
metabolic syndrome [6]. Applying the recommended cut-
offs for white people of European origin classified a large
portion of this Norwegian population as having central
obesity. In women aged 60 years or more, three out of
four were defined as obese. As central obesity is regarded
as a likely early step in the development of full metabolic
syndrome [6,10], this definition puts a very large number
of individuals belonging to one of the longest living and
healthiest populations in the world [11] at increased risk
for cardiovascular disease and type 2 diabetes.
The IDF definition classified the majority of our popula-
tion as hypertensive. Mean blood pressure in the HUNT 2
population increased markedly with age, especially
among women. As the IDF definition, like other defini-
tions of the metabolic syndrome, has not included any
adjustment for age, 90% of those aged 60 years or more
would be defined as being hypertensive.
The prevalence of the metabolic syndrome by the IDF cri-
teria was higher than by the 2005 ATP III criteria in all sex-
stratified age groups except in men 20–29 years old. As the
two definitions are based on much of the same compo-
nents, the difference in prevalence was mainly related to
different waist circumference and to the focus on central
obesity as an obligatory component in the IDF definition
in contrast to being one out of five equally weighted com-
ponents in the 2005 ATP III definition.
Table 3: Characteristics of fasting1 versus non-fasting participants by sex, the HUNT 2 study
Men Women
Fasting1 Non fasting Fasting1 Non fasting
N (%) 5101
(17.0%)
24,914
(83.0%)
5105
(15.2%)
28,480
(84.8%)
Categorical measures, 
% (95% CI)
Odds ratio Odds ratio
IDF-proxy for 
metabolic syndrome2
13.8
(12.8–14.7)
14.4
(14.0–14.9)
1.05
(0.97–1.15)
14.8
(13.9–15.8)
13.8
(13.4–14.2)
0.92
(0.85–1.00)
ATP-proxy for 
metabolic syndrome3
5.8
(5.2–6.5)
5.8
(5.5–6.1)
1.00
(0.88–1.14)
9.8
(8.9–10.6)
9.0
(8.7–9.4)
0.92
(0.83–1.02)
Type 2 diabetes 1.6
(1.2–1.9)
1.9
(1.7–2.0)
1.18
(0.93–1.49)
2.0
(1.6–2.4)
1.6
(1.5–1.8)
0.81
(0.65–1.01)
Antihypertensive 
medication
10.3
(9.5–11.1)
10.3
(9.9–10.6)
1.00
(0.90–1.10)
13.1
(12.2–14.0)
11.6
(11.2–12.0)
0.87*
(0.80–0.96)
Continuous measures, 
means (95% CI)
Mean z-score diff. Mean z-score diff.
Age, y 48.4
(48.0–48.9)
50.0
(49.8–50.2)
0.093* 49.4
(48.9–49.8)
50.2
(50.0–50.4)
0.048*
Systolic blood 
pressure, mm Hg
140.4
(139.8–140.9)
140.0
(139.7–140.2)
-0.022 137.3
(136.6–137.9)
135.8
(135.5–136.1)
-0.062*
Diastolic blood 
pressure, mm Hg
83.4
(83.0–83.7)
81.7
(81.6–81.9)
-0.138* 80.0
(79.6–80.3)
78.7
(78.6–78.9)
-0.101*
Waist circumference, 
cm
92.2
(91.9–92.5)
91.9
(91.8–92.0)
-0.028 82.0
(81.7–82.4)
81.5
(81.4–81.6)
-0.050*
HDL cholesterol, 
mmol/L
1.26
(1.25–1.27)
1.24
(1.23–1.24)
-0.063* 1.50
(1.49–1.52)
1.49
(1.49–1.50)
-0.029
Triglycerides, mmol/L 1.73
(1.70–1.76)
2.02
(2.01–2.04)
0.240* 1.44
(1.42–1.47)
1.59
(1.58–1.60)
0.153*
Glucose, mmol/L 5.30
(5.27–5.33)
5.60
(5.58–5.62)
0.185* 5.20
(5.17–5.23)
5.41
(5.40–5.43)
0.150*
HUNT, the Nord-Trøndelag Health study; CI, confidence interval; IDF, the International Diabetes Federation; ATP, the National Cholesterol Education
Program-Adult Treatment Panel III; HDL, high-density lipoprotein.
*P < 0.05.
1Four to nine hours or more since the last meal.
2IDF-proxy for metabolic syndrome defined as IDF-central obesity plus any two of three components (low HDL cholesterol, high blood pressure or treatment for previously 
diagnosed hypertension, or previously diagnosed type 2 diabetes).
3ATP-proxy for metabolic syndrome defined as any three of four components (ATP III-defined central obesity, low HDL cholesterol, high blood pressure or treatment for 
previously diagnosed hypertension, or previously diagnosed type 2 diabetes).BMC Public Health 2007, 7:220 http://www.biomedcentral.com/1471-2458/7/220
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Several population studies have reported an increase in
the prevalence of the metabolic syndrome with age
regardless of definition [12-31], although some have
reported a peak in the seventh decade and then a decline
in both sexes [12,19,23,31] or only in men
[13,14,18,22,26,30]. However, this has been incom-
pletely studied in European populations, where only one
study from Greece has assessed age-specific prevalence
using the IDF definition [23]. In addition, to our knowl-
edge, only one study worldwide has previously assessed
the prevalence separately for those aged 80 years and
above [31]. In contrast to several other studies [12-
14,18,19,22,23,26,31], we found that the prevalence of
the metabolic syndrome, by both definitions, increased
linearly with age beyond the seventh decade in both sexes.
To our knowledge, our study is the first to show that this
increase continued into the ninth decade.
Strengths and limitations
The HUNT 2 study covered the whole adult population
(homogenous, <3% non-Caucasian) in Nord-Trøndelag
County, which is considered fairly representative of Nor-
way. The county is mostly rural; the largest of six small
towns has a population of 21,000. The main objectives of
the HUNT study concerned large public health issues like
diabetes, cardiovascular disease, obstructive lung disease,
osteoporosis and mental health [9].
The participation rate was age dependent, with the highest
participation rate (85.6%) in the age group 60–69 years.
A study of non-participants [9] showed that the main rea-
sons for not attending were of a practical nature in young
people and poor health in elderly people. There is a
potential selection bias from non-participation, although
the participation rate in the HUNT study was similar to or
higher than in comparable population studies [9].
A limitation of the HUNT study is that it was impractical
to request the whole population to be fasting since exam-
inations were spread out during daytime. Blood sampling
was done whenever participants attended. However, our
estimates of prevalence of the metabolic syndrome based
on the sub-sample of participants reporting ≥4 hours fast-
ing should be quite representative for the entire HUNT 2
population as the statistically significant differences
between fasting and non-fasting participants were all
minor (except triglycerides and glucose). Further, using
the proxies of IDF and ATP metabolic syndrome, we were
unable to reveal any statistically significant difference
between fasting and non-fasting participants. Our adjust-
ment of the levels of plasma glucose and triglycerides
among the included individuals reporting 4–8 hours fast-
ing should further increase the validity of our findings.
Other referenced prevalence studies have used 6 hours
fasting without adjustments [15,31,32].
Management of metabolic syndrome
The IDF Epidemiology Task Force Consensus Group [6]
states, "Researchers and clinicians should use the new cri-
teria for the identification of high-risk individuals and for
research studies. Preventive measures are obviously
needed in people identified". According to the AHA/
NHLBI Scientific Statement 2005, the prime emphasis in
individuals with metabolic syndrome is to mitigate the
underlying risk factors (obesity, physical inactivity, and
atherogenic diet) through lifestyle changes [7]. In addi-
tion, 10-year risk assessment (e.g. age, gender, total cho-
lesterol, smoking status) for cardiovascular disease should
be carried out with algorithms such as the Framingham
risk score [1,7,33].
All components of the IDF criteria can easily be measured
in primary care and used as tools for counselling. How-
ever, when the majority of elderly individuals are defined
as being in need of risk management, this becomes a chal-
lenge both for clinicians and researchers. It seems ethical
questionable to identify such a large part of the popula-
tion as being at risk, particularly since there still is doubt
regarding the value of the metabolic syndrome as a risk
marker. On the one hand, data indicate that the metabolic
syndrome carries increased long-term risk both for cardi-
ovascular disease and diabetes as well as a short-term risk
[33]. On the other hand, the meaning of the metabolic
syndrome as a cardiovascular risk factor independent of
other conventional risk factors (e.g., smoking, family his-
tory) has been questioned [34]. In addition, few studies
have examined whether this risk factor is as strong in eld-
erly individuals as it is in younger or middle-aged individ-
uals. A recent study among Swedish men followed for a
maximum of 33 years found that the metabolic syndrome
was an independent risk factor in middle age but not con-
sistently in elderly men for cardiovascular and total mor-
tality, when established cardiovascular risk factors were
taken into account [35]. Other studies among elderly peo-
ple have not been conclusive: in British women, the syn-
drome was found only modestly associated with risk of
coronary heart events in un-adjusted analyses, and not
associated when adjusted for other risk factors [32], and in
American men and women, the syndrome was found
associated with increased cardiovascular events but not
with total mortality [36].
Thus, implementation of the recent IDF and AHA/NHLBI
guidelines for clinical management of the metabolic syn-
drome in elderly individuals may seem somewhat prema-
ture. First, further data are needed to assess the risk for
cardiovascular and total mortality. Secondly, as the meta-
bolic syndrome is not a reliable tool for overall risk assess-
ment in the short term but more carries increased long-
term risk [33], this may be of lower value among elderly
than among younger people. Thirdly, our findings shouldBMC Public Health 2007, 7:220 http://www.biomedcentral.com/1471-2458/7/220
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give increased attention to the practical, ethical, and eco-
nomic aspects of classifying a very high portion of asymp-
tomatic elderly individuals as in need of counselling,
overall risk assessment for cardiovascular disease, and
long-term follow-up.
Conclusion
We found a high prevalence of the metabolic syndrome in
Norwegian adults aged 20–89 years, particularly by using
the IDF criteria. Our findings of increasing prevalence
right up to the ninth decade highlight the need for further
studies to assess if the associated risks are the same in eld-
erly people as what have been found in younger people.
Hopefully, this will clarify if the metabolic syndrome is a
meaningful diagnosis in elderly people.
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